Long-acting buprenorphine formulations as a new strategy for the treatment of opioid use disorder
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Maremmani, Icro
- dc.contributor.author Dematteis, Maurice
- dc.contributor.author Gorzelanczyk, Edward J.
- dc.contributor.author Mugelli, Alessandro
- dc.contributor.author Walcher, Stephan
- dc.contributor.author Torrens, Marta
- dc.date.accessioned 2025-02-03T15:18:46Z
- dc.date.available 2025-02-03T15:18:46Z
- dc.date.issued 2023
- dc.description.abstract Long-acting buprenorphine formulations have been recently marketed for the Opioid Agonist Treatment (OAT) of opioid use disorder (OUD) associated with medical, social, and psychological support. Their duration of action ranges from one week up to 6 months. The non-medical use of opioids is increasing with a parallel rise in lethal overdoses. Methadone and buprenorphine are the standard treatment for opioid dependence. Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing the risks of overdose, crime, and transmission of HIV (Human Immunodeficiency Virus) in people who use opioids; however, its effectiveness has been hindered by low rates of uptake and retention in treatment. Furthermore, both methadone and buprenorphine are widely diverted and misused. Thus, a crucial aspect of treating OUD is facilitating patients' access to treatment while minimizing substance-related harm and improving quality of life. The newly developed long-acting buprenorphine formulations represent a significant change in the paradigm of OUD treatment, allowing an approach individualized to patients' needs. Strengths of this individualized approach are improved adherence (lack of peaks and troughs in blood concentrations) and a reduced stigma since the patient doesn't need to attend their clinic daily or nearly daily, thus facilitating social and occupational integrations as the quality of life. However, less frequent attendance at the clinic should not affect the patient-physician relationship. Therefore, teleconsulting or digital therapeutic services should be developed in parallel. In addition, diversion and intravenous misuse of buprenorphine are unlikely due to the characteristics of these formulations. These features make this approach of interest for treating OUD in particular settings, such as subjects staying or when released from prison or those receiving long-term residential treatment for OUD in the therapeutic communities. The long-lasting formulations of buprenorphine can positively impact the OUD treatment and suggest future medical and logistic developments to maximize their personalized management and impact.
- dc.format.mimetype application/pdf
- dc.identifier.citation Maremmani I, Dematteis M, Gorzelanczyk EJ, Mugelli A, Walcher S, Torrens M. Long-acting buprenorphine formulations as a new strategy for the treatment of opioid use disorder. J Clin Med. 2023 Aug 26;12(17):5575. DOI: 10.3390/jcm12175575
- dc.identifier.doi http://dx.doi.org/10.3390/jcm12175575
- dc.identifier.issn 2077-0383
- dc.identifier.uri http://hdl.handle.net/10230/69457
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof J Clin Med. 2023 Aug 26;12(17):5575
- dc.rights © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword OUD particular settings
- dc.subject.keyword Impact on OUD treatments
- dc.subject.keyword Long-acting buprenorphine medications
- dc.title Long-acting buprenorphine formulations as a new strategy for the treatment of opioid use disorder
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion